Some Colorectal Cancers Are " Born To Be Bad, " Have Already Spread Long Before Diagnosis

Four out of five metastatic colorectal cancers have already spread long before people are diagnosed, shows new study.
Source: Healthcare News - Category: Pharmaceuticals Authors: Source Type: news

Related Links:

Publication date: Available online 16 July 2019Source: International Journal of PharmaceuticsAuthor(s): Ana Rita Sousa, Ana Vanessa Oliveira, Maria José Oliveira, Bruno SarmentoAbstractColorectal cancer (CRC) is the second most common cause of cancer-related death in the world, mainly due to distant metastases events. The metastatic CRC (mCRC) stages are resistant to the therapeutic recommended. Therefore, it urges the development of more efficient strategies to impair the disease. Small interfering RNA (siRNA) is a well-known silencing tool with impact on targeted cancer therapy, even though in vivo challenges diff...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
Publication date: October 2019Source: Cancer Epidemiology, Volume 62Author(s): Said Abasse Kassim, Weiyan Tang, Muhammad Abbas, Shenzhen Wu, Qingdao Meng, Chengcheng Zhang, Xiaobo Li, Rui ChenAbstractPoor survival among colorectal cancer (CRC) patients has been widely associated with clinico-epidemiological features and treatment regimen. In Jiangsu (China), however, it is not known which one of the prognostic factors explains the survival disparities among patients with CRC. This prospective study using 1078 patients (stages I-IV) that underwent surgery at Jiangsu Hospital, explored the relevant factors affecting the prog...
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
Publication date: 16 July 2019Source: Cell Reports, Volume 28, Issue 3Author(s): Teresa Olbrich, Maria Vega-Sendino, Matilde Murga, Guillermo de Carcer, Marcos Malumbres, Sagrario Ortega, Sergio Ruiz, Oscar Fernandez-CapetilloSummaryThe recent availability of somatic haploid cell lines has provided a unique tool for genetic studies in mammals. However, the percentage of haploid cells rapidly decreases in these cell lines, which we recently showed is due to their overgrowth by diploid cells present in the cultures. Based on this property, we have now performed a phenotypic chemical screen in human haploid HAP1 cells aiming ...
Source: Cell Reports - Category: Cytology Source Type: research
Authors: Li L, Wang H, Qian J, Wei G, Ding R, Hu C, Fang D, Jiang Z, Bi L, Song J, Ma J, Qin F, Huang X, Cao M, Huo J Abstract The traditional Chinese medicine decoction FuFangChangTai (FFCT) has been used in the therapy of colon cancer clinically, yielding alleviated toxicity and enhanced immunity. In our previous study, FFCT exerted its antitumor activity not only by inducing apoptosis but also by activating autophagy to eliminate tumor cells. However, its mechanism is not well understood. The purpose of this study was to investigate the relationship between macrophages activation and FFCT-induced autophagy. Resu...
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research
ConclusionIn conclusion, this study showed that Aloe vera extract and its active component aloin activated the Wnt/β-catenin pathway and inhibited the Notch pathway in the presence of Wnt3a. While another active component, aloesin, activated the Wnt/β-catenin pathway and inhibited the Notch signaling pathway independent of Wnt3a. Given that Wnt/β-catenin and Notch pathway are closely associated with the progression of CRC, these findings would be helpful to better understand the colonic carcinogenicity of Aloe vera.Graphical abstract
Source: Journal of Ethnopharmacology - Category: Drugs & Pharmacology Source Type: research
Source: OncoTargets and Therapy - Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
Tougeron Thierry Lecomte Florence Mary Thomas Aparicio Lysiane Marthey Helene Blons Dewi Vernerey Pierre Laurent-Puig In patients with metastatic colorectal cancer (mCRC), RAS and BRAF mutations are currently determined by tumor sample analysis. Here, we report BRAF mutation status analysis in paired tumor tissue and plasma samples of mCRC patients included in the AGEO RASANC prospective cohort study. Four hundred and twenty-five patients were enrolled. Plasma samples were analyzed by next-generation sequencing (NGS). When no mutation was identified, we used two methylated specific biomarkers (digital dr...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
ConclusionThe differences in EZH2 expression between tumor center and invasion front as well as different scoring and cutoff values can most likely explain controversial literature data concerning the prognostic value of EZH2. Epigenetic therapies using EZH2 inhibitors have to be carefully evaluated for each specific tumor type, since alterations in cell differentiation might lead to unfavorable results.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
British Journal of Cancer, Published online: 17 July 2019; doi:10.1038/s41416-019-0525-3Relationship of telomere length in colorectal cancer patients with cancer phenotype and patient prognosis
Source: British Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
Conclusion.The outcomes of this study were consistent with those of clinical trials. There were no new safety concerns. Regorafenib treatment would not be recommended for patients with higher PS.Implications for Practice.Previous clinical trials demonstrated regorafenib improved overall survival in patients with metastatic colorectal cancer who progress after standard chemotherapies. Because the eligibility criteria of the trials were restricted compared with a real‐world setting, the data from the trials may not fully represent the profiles of regorafenib in clinical practice. This large‐scale observational study show...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Gastrointestinal Cancer Source Type: research
More News: Cancer | Cancer & Oncology | Colorectal Cancer | Pharmaceuticals | Study